Economic Implications of Treatment-Resistant Depression Among Employees
- 1 January 2004
- journal article
- Published by Springer Science and Business Media LLC in PharmacoEconomics
- Vol. 22 (6), 363-373
- https://doi.org/10.2165/00019053-200422060-00003
Abstract
No abstract availableKeywords
This publication has 25 references indexed in Scilit:
- What Role Do Atypical Antipsychotic Drugs Have in Treatment-Resistant Depression?British Journal of Psychology, 2002
- Vagus Nerve Stimulation (VNS™) for Treatment-Resistant Depression Efficacy, Side Effects, and Predictors of OutcomeNeuropsychopharmacology, 2001
- Cost of depression: current assessment and future directionsExpert Review of Pharmacoeconomics & Outcomes Research, 2001
- Social Functioning in DepressionThe Journal of Clinical Psychiatry, 2000
- DEFINITION AND EPIDEMIOLOGY OF TREATMENT-RESISTANT DEPRESSIONPsychiatric Clinics of North America, 1996
- Antihypertensive pharmacotherapy: Economic outcomes in a health maintenance organizationCurrent Therapeutic Research, 1994
- The deliberate misdiagnosis of major depression in primary careArchives of Family Medicine, 1994
- Treatment-Resistant Depression: A Critique of Current ApproachesAustralian & New Zealand Journal of Psychiatry, 1994
- Lifetime and 12-Month Prevalence of DSM-III-R Psychiatric Disorders in the United StatesArchives of General Psychiatry, 1994
- Lithium Augmentation in Antidepressant-Resistant Patients a Quantitative AnalysisThe British Journal of Psychiatry, 1991